Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3720 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

NeoPharm colorectal cancer drug misses target

While the interim analysis of data following the completion of treatment of the first 21 patients demonstrated disease stabilization, the study did not achieve the primary tumor response

Cephalon sleep drug requires warning label

The FDA also said that there would have to be a warning section for the company’s older drug for sleepiness Provigil. The draft labeling includes a proposed bolded

Baxter blood clotting drug authorized by FDA

Severe congenital Protein C deficiency results in a hypercoagulable state, meaning there is an abnormal tendency for blood clotting. This can cause severe, often life-threatening blood clots in

EU approves Roche stomach cancer drug

Oral chemotherapy Xeloda is already replacing standard intravenous therapy 5-fluorouracil (5-FU) in other gastrointestinal cancers. Xeloda on its own is already available in colorectal cancer that has spread

Astellas in licensing deal with Regeneron

Astellas will pay $20 million upfront and will make up to five additional annual payments of $20 million. Upon commercialization of any antibody products discovered utilizing VelocImmune, Astellas

KV Pharmaceutical buys menopause therapy

Vivus is eligible to receive an upfront payment of $10 million upon the closing and an additional $140 million upon the approval of the new drug application for